ArticleCureus2025
Anti-Gamma-Aminobutyric Acid B (GABA-B) Receptor Encephalitis: A Case Series Analyzing Treatment Modalities and Cancer Screening Recommendations.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case series presents an alternative treatment approach for refractory epilepsy in the setting of anti-gamma-aminobutyric acid B receptor (GABA-B-R) encephalitis and examines current guidelines for long-term cancer screening. We present two cases of anti-GABA-B receptor encephalitis from Kansas City, Missouri. The first case describes a 53-year-old woman presenting with new-onset headache, seizures, and progressive encephalopathy, who was treated with corticosteroids and anti-seizure medications, followed by intravenous immunoglobulin (IVIG) and plasma exchange (PLEX). Cancer screening with chest CT was negative. Fluorodeoxyglucose (FDG)-PET revealed increased uptake in two cervical lymph nodes; however, her biopsy was negative for malignancy. The second case describes a 49-year-old woman presenting with confusion, dizziness, and seizures. Her seizures were refractory to anti-seizure medications and immunotherapy, but an excellent response and recovery were seen after the concurrent use of methylprednisolone, IVIG, and anti-seizure medications. Subsequent malignancy screenings remained negative in both cases. A combination of corticosteroids with IVIG or PLEX may be a promising option for refractory cases of anti-GABA-B-R autoimmune encephalitis (AE). Additionally, it is not clear whether malignancies other than small cell lung carcinoma (SCLC) are strongly associated with this condition. Further studies are needed to evaluate the option of combined immunotherapy and the association of other malignancies with anti-GABA-B AE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.